Top 10 Stock Picks of Roberto Mignone’s Bridger Management

Published on September 15, 2022 at 9:11 am by Swati Goyal in Hedge Funds, News

In this article, we discuss the top 10 stock picks of Roberto Mignone’s Bridger Management. If you want to skip our detailed analysis of Mignone’s history, investment philosophy, and hedge fund performance, go directly to Top 5 Stock Picks of Roberto Mignone’s Bridger Management.

Roberto Mignone established Bridger Management in the year 2000. He pursued his MBA at the Harvard University Graduate School of Business Administration after receiving a Bachelor of Arts in Classics from Harvard College. Before starting his own investment company, Mignone was one of the founding partners of Blue Ridge Capital in 1996, together with John Griffin. Blake Goodner, a junior analyst in healthcare, chose to help Mignone after he left Blue Ridge Capital to launch his hedge fund. This could be a contributing element as to why the fund decided to invest approximately 35% of the money in its portfolio in the healthcare industry, second only to the financial sector, which accounted for 49% of the portfolio’s value. Even further back, Mignone had worked for Julian Robertson’s Tiger Management, earning the prestigious title of “tiger cub”. Currently, he is the managing partner at Bridger Management.

Bridger Management, a multi-billion dollar investment management firm with offices in New York, focuses on long-term equity strategies. The company’s main investment objective is to produce long-term, risk-adjusted capital growth, frequently through making investments in equities, securities, and other products with a stock market connection. Bridger Management has focused on the healthcare sector since its establishment and amassed a large amount of research information to back its investments. The hedge fund also invests in communications, consumer goods, and financial services firms.

As of Q2 2022, Bridger Management holds a 13F portfolio valued at $443.62 million, down from $609.73 million in the previous quarter. Some of the hedge fund’s notable holdings in the second quarter included Charter Communications, Inc. (NASDAQ:CHTR), Morgan Stanley (NYSE:MS), and Centene Corporation (NYSE:CNC).

Our Methodology

Let’s start our list of the top 10 stocks selected by Roberto Mignone’s Bridger Management with this economic outlook in mind. These equities were selected from Mignone’s Q2 portfolio. Using a comprehensive database of 895 elite hedge funds monitored by Insider Monkey in the second quarter of 2022, the popularity of each firm among hedge funds was calculated.

Top Stock Picks of Roberto Mignone’s Bridger Management

10. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Bridger Management’s Stake Value: $17,220,000

Percentage of Bridger Management’s 13F Portfolio: 3.88%

Number of Hedge Fund Holders: 59

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), which is situated in San Rafael, California, creates medications to treat rare genetic diseases and conditions, including Duchenne muscular dystrophy and haemophilia. Bridger Management acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the second quarter of 2022, owning 207,800 shares worth $17.22 million.

Among the hedge funds being tracked by Insider Monkey, Julian Baker and Felix Baker’s Baker Bros. Advisors is the most significant shareholder of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), with a $631.51 million stake in the company.

On August 9, Christopher Raymond, an analyst at Piper Sandler, boosted his price objective on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) from $125 to $128 while maintaining an ‘Overweight’ rating.

Fund managers added to their BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) holdings in the second quarter. Insider Monkey’s data shows that 59 elite hedge funds held stakes in the company at the end of the second quarter, up from 56 funds a quarter earlier.

Along with Charter Communications, Inc. (NASDAQ:CHTR), Morgan Stanley (NYSE:MS), and Centene Corporation (NYSE:CNC), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the stocks that Bridger Management is monitoring.

9. Uber Technologies, Inc. (NYSE:UBER)

Bridger Management’s Stake Value: $20,323,000

Percentage of Bridger Management’s 13F Portfolio: 4.58%

Number of Hedge Fund Holders: 129

Uber Technologies, Inc. (NYSE:UBER) is a company that creates and runs proprietary technology applications in the United States, Canada, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. Uber Technologies, Inc. (NYSE:UBER) stated on September 1 that it will collaborate with financial technology firm Moove to raise the number of electric vehicles in London by 10,000 over the ensuing few years.

On August 3, MKM Partners analyst Rohit Kulkarni reaffirmed a ‘Buy’ recommendation on Uber Technologies, Inc. (NYSE:UBER) while increasing his price objective to $40 from $32. The company’s Q2 witnessed another clean beat, and the Q3 bookings prediction was once more above consensus expectations, according to the analyst’s research note to investors.

Uber Technologies, Inc. (NYSE:UBER) was in 129 hedge fund portfolios at the end of the second quarter of 2022. There were 144 hedge funds in our database with UBER at the end of the previous quarter. In the second quarter, Bridger Management reduced its stake in Uber Technologies, Inc. (NYSE:UBER) by 3%, and its position is now worth about $20.32 million. Ken Fisher’s Fisher Asset Management is the most significant stakeholder of Uber Technologies, Inc. (NYSE:UBER), with 24.48 million shares worth $500.83 million.

ClearBridge Investments mentioned Uber Technologies, Inc. (NYSE:UBER) in its Q3 2021 investor letter. Here’s what the fund said:

“We have also been looking for multiyear secular trends outside of the IT and Internet sectors to help us maintain a portfolio that can perform well in markets with varied sector or factor leadership. In particular, electrification of the global economy and the transition to electric vehicles (EVs) are areas where we continue to add exposure. We are investing in the brains behind EVs through NXP in the control center and Aptiv for safety features. Global rideshare leader Uber will also be a key player in the transition from internal combustion engines to EVs.”

8. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Bridger Management’s Stake Value: $20,591,000

Percentage of Bridger Management’s 13F Portfolio: 4.64%

Number of Hedge Fund Holders: 45

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company that conducts research and markets cystic fibrosis medications. The business boosted its 2022 revenue projection in its Q2 2022 report, which Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) published on August 4. The biotech now expects full-year sales of $8.6 billion-$8.8 billion, up from $8.4 billion-$8.6 billion.

After Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s Q2 results beat and revised expectations, Piper Sandler analyst Do Kim increased his price objective on the company to $288 from $256 on August 16 while retaining a ‘Neutral’ rating on the shares. Overall, 45 hedge funds were bullish on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) at the end of June 2022, holding collective stakes amounting to approximately $2.27 billion.

In the second quarter of 2022, Bridger Management held 73,072 shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) worth over $20.59 million, representing 4.64% of the firm’s total portfolio. As of June 30, Renaissance Technologies owned 1.76 million shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and is the company’s largest shareholder.

On September 2, the FDA approved the use of Orkambi, a medication created by Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), to treat children between the ages of 12 and 24 months who have cystic fibrosis (CF). The FDA had previously advised using Orkambi for CF patients with two copies of the F508del mutation who were two years of age or older.

Baron Funds, an asset management firm, mentioned Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in its second quarter 2022 investor letter. Here is what the fund said:

“Vertex Pharmaceuticals Incorporated is a leader in the treatment of cystic fibrosis, a fatal lifelong disease that Vertex has made major steps towards curing. Shares increased mostly due to underlying business fundamentals that include strong free cash flow generation and a pipeline that is finally starting to add value. We expect Vertex’s kidney disease program and updates to treat Type 1 diabetes to drive future upside.”

7. Alcon Inc. (NYSE:ALC)

Bridger Management’s Stake Value: $21,884,000

Percentage of Bridger Management’s 13F Portfolio: 4.93%

Number of Hedge Fund Holders: 26

Alcon Inc. (NYSE:ALC) develops, manufactures, and markets products for treating eye disorders and diseases, such as surgical instruments, eye drops, and consumer vision care products. Alcon Inc. (NYSE:ALC) and Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced they had signed a legally binding merger agreement on August 23. As a result, Alcon would acquire Aerie for around $770 million.

Yigal Nochomovitz, a Citi analyst, downgraded Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) on August 29 from ‘Buy’ to ‘Neutral’ with a price objective of $15.25, up from $14, highlighting the company’s upcoming acquisition by Alcon Inc. (NYSE:ALC).

26 hedge funds were long Alcon Inc. (NYSE:ALC) at the end of the second quarter, up from 24 in the preceding quarter. The total value of Q2 hedge fund holdings stood at $982.28 million. Nicolai Tangen’s Ako Capital, with 4.69 million shares worth $327.65 million, is the most significant stakeholder of Alcon Inc. (NYSE:ALC).

Bridger Management first invested in Alcon Inc. (NYSE:ALC) in the second quarter of 2019. The hedge fund cut its stake in Alcon Inc. (NYSE:ALC) by 40,100 shares in the second quarter, reducing its total stake size by 12%. However, Roberto Mignone’s Bridger Management still holds 313,115 shares of Alcon Inc. (NYSE:ALC), worth more than $21.88 million.

6. Clarivate Plc (NYSE:CLVT)

Bridger Management’s Stake Value: $22,749,000

Percentage of Bridger Management’s 13F Portfolio: 5.12%

Number of Hedge Fund Holders: 31

Clarivate Plc (NYSE:CLVT) provides trustworthy analytics and insights to quicken the pace of innovation. The company’s products include Life Science, Web of Science, Cortellis, Derwent, CompuMark, MarkMonitor, and Techstreet. With about 116.67 million shares valued at $1.62 billion, Leonard Green & Partners is the biggest shareholder of Clarivate Plc (NYSE:CLVT).

According to its 13F filing for the second quarter of 2022, Bridger Management held over 1.64 million shares of Clarivate Plc (NYSE:CLVT), amounting to $22.75 million and representing 5.12% of the fund’s 13F portfolio. However, the hedge fund cut its stake in the firm by 11% during Q2.

On July 12, Wells Fargo analyst Seth Weber initiated coverage of Clarivate Plc (NYSE:CLVT), assigning the stock an ‘Overweight’ rating and a $20 price target. In addition, 31 hedge funds reported having bullish bets on Clarivate Plc (NYSE:CLVT) as of the end of the second quarter, with combined stakes valued at $3.38 billion.

Clarivate Plc (NYSE:CLVT) is a significant stock in Bridger Management’s portfolio, along with Charter Communications, Inc. (NASDAQ:CHTR), Morgan Stanley (NYSE:MS), and Centene Corporation (NYSE:CNC).

Baron Funds, mentioned Clarivate (NYSE:CLVT) in its Q1 2022 investor letter. Here’s is what the fund said:

“We reduced our stake in Clarivate Plc (NYSE:CLVT), an information services company focused on the scientific and academic markets, after the company reported particularly disappointing fourth quarter earnings results.”

Click to continue reading and see Top 5 Stock Picks of Roberto Mignone’s Bridger Management.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up